119th Congress · introduced in the House · Dec 18, 2025
NIH Clinical Trial Integrity Act
Official title from Congress.gov
Latest action (Dec 18, 2025): Referred to the House Committee on Energy and Commerce.
View on Congress.govPolicy area: Health
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
4 citations.
BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · lobbying firm or registrant: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$120,000
Spent on own lobbying
HJRes 197 / SJRes 197, CRA related to the 2027 NBPP; HR 247 / S 46, Health Care Affordability Act; HR 6867 / S 3562, the NIH Clinical Trial Integrity Act; HR 3521 / S 4440, the Clinical Trial Modernization Act; HR 4710 / S 2420, No Surprises Act Enforcement Act; HR…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · lobbying firm or registrant: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$590,000
Spent on own lobbying
…HR 5582, S 2355, the Patients Deserve Price Tags Act; HR 6248 / S 4027, Healthy Competition for Better Care Act HR 6485 / S 43, Skinny Labels, Big Savings Act; HR 6867 / S 3562, NIH Clinical Trial Integrity Act; HR 7895, the PBM Kickback Prohibition Act; HR 8908, the STOP GAMES Act; HR 9393, Lower Costs, More Transparency Act…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN · lobbying firm or registrant: THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$70,000
Spent on own lobbying
…h Education and Awareness Requires Learning Young Act of 2009. H.Res.806 - Supporting the recognition of October 2025 as National Breast Cancer Awareness Month H.R.6867/S.3564 - Clinical Trial Integrity Act; a bill to direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of H…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PATIENT ACCESS NETWORK FOUNDATION · lobbying firm or registrant: VENABLE LLP
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 6, 2026 · issue area: Health Issues
$40,000
Paid to lobbying firm
…Enhance Premium Tax Credits; Reduce barriers to participation in clinical trials (H.R. 3521, H.R. 4184) and increase participation of underrepresented groups (H.R. 6867/S.3564); Increase CMS outreach and education on the Medicare Prescription Payment Program, Increasing Medication Access for Seniors Act (H.R. 6401).
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing